Valuation: HST Global, Inc.

Market Cap 140M 127M 117M 106M 199M 13.17B 206M 1.41B 558M 7.04B 524M 513M 22.33B P/E 2023
-21.8x
P/E 2024 -176x
Enterprise Value 140M 127M 118M 106M 200M 13.23B 207M 1.41B 560M 7.07B 526M 515M 22.43B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
70.95%
Yield 2023 *
-
Yield 2024 -
1 week-10.71%
Current month-10.71%
1 month-10.71%
3 months-3.85%
6 months+25.00%
Current year-36.87%
1 month 0.13
Extreme 0.1337
0.7
Current year 0.06
Extreme 0.063
0.99
1 year 0.06
Extreme 0.063
1
3 years 0
Extreme 0.0001
1.15
5 years 0
Extreme 0.0001
1.15
10 years 0
Extreme 0
1.15
Manager TitleAgeSince
Chief Executive Officer - 07/10/2025
Director of Finance/CFO 57 26/04/2024
Director TitleAgeSince
Director/Board Member 57 26/04/2024
Director/Board Member - 07/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
13/05/24 Other

Chairperson

19,791,060 47.6190%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.71%+941.67%+22.55% 209M
-2.69%-5.28%+58.42%+65.89% 68.45B
-0.92%+7.70%+12.90%+93.35% 61.31B
0.00%-0.95%+20.09%+99.04% 55.73B
+0.05%+2.22%+12.94%+109.21% 47.51B
-2.24%-2.05%+19.11%+37.48% 44.68B
-2.32%-10.26%+168.03%+778.17% 38.14B
+2.15%-0.47%+22.85%+56.09% 35.85B
-2.32%-5.14%+75.43%+60.15% 33.05B
+2.61%+5.78%-36.63%+406.34% 25.9B
Average -0.52%+2.17%+129.48%+172.83% 41B
Weighted average by Cap. -0.82%+2.25%+39.79%+162.66%

Financials

2023 2024
Net sales - -
Net income -146K -132K -123K -111K -208K -13.79M -216K -1.47M -584K -7.36M -549K -537K -23.38M -213K -193K -178K -161K -303K -20.05M -314K -2.14M -849K -10.71M -798K -781K -33.99M
Net Debt 96.79K 87.71K 81.13K 73.2K 138K 9.13M 143K 975K 386K 4.88M 363K 356K 15.48M 580K 526K 487K 439K 827K 54.73M 856K 5.84M 2.32M 29.24M 2.18M 2.13M 92.81M
Projected Income Statement - Annual - HST Global, Inc.
Logo HST Global, Inc.
HST Global, Inc. is an integrated health and wellness biotechnology company. The Company is focused on developing and /or acquiring a network of wellness centers worldwide that is primarily focused on the homeopathic and alternative treatment of late-stage cancer. The Company intends to acquire innovative products for the treatment of life-threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late-stage cancer and/or life-threatening diseases. It is also focused on funding and developing cutting-edge software solutions. The Company has not generated any revenue.
Employees
2
  1. Stock Market
  2. Stocks
  3. HSTC Stock